Mast cell: A multi-functional master cell

Frontiers in Immunology

Volumn 6, Issue JAN, 2016, Pages

  Krystel Whittemore, Melissa ^a   Dileepan, Kottarappat N ^a   Wood, John G ^a  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

Atherogenesis; Immune system; Inflammatory mediators; Mast cell; Systemic hypoxia

Indexed keywords

IMMUNOGLOBULIN E; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; INTERLEUKIN 4; INTERLEUKIN 6; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN LIKE RECEPTOR; PATHOGEN ASSOCIATED MOLECULAR PATTERN; TUMOR NECROSIS FACTOR ALPHA;

ADAPTIVE IMMUNITY; ANGIOGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; DEGRANULATION; HEART ARRHYTHMIA; HOMEOSTASIS; HUMAN; HYPOXIA; IMMUNE RESPONSE; INNATE IMMUNITY; ISCHEMIA; MAST CELL; NEUTROPHIL; NONHUMAN; REPERFUSION INJURY; REVIEW;

EID: 84958170864     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2015.00620     Document Type: Review

References (137)

1. da Silva EZ, Jamur MC, Oliver C. Mast cell function: a new vision of an old cell. J Histochem Cytochem (2014) 62(10):698-738. doi:10.1369/0022155414545334
2. Galli SJ, Tsai M. Mast cells in allergy and infection: versatile effector and regulatory cells in innate and adaptive immunity. Eur J Immunol (2010) 40(7):1843-51. doi:10.1002/eji.201040559
3. Jamur MC, Grodzki AC, Berenstein EH, Hamawy MM, Siraganian RP, Oliver C. Identification and characterization of undifferentiated mast cells in mouse bone marrow. Blood (2005) 105(11):4282-9. doi:10.1182/blood-2004-02-0756
4. Metcalfe DD, Boyce JA. Mast cell biology in evolution. J Allergy Clin Immunol (2006) 117(6):1227-9. doi:10.1016/j.jaci.2006.03.031
5. Collington SJ, Williams TJ, Weller CL. Mechanisms underlying the localisation of mast cells in tissues. Trends Immunol (2011) 32(10):478-85. doi:10.1016/j.it.2011.08.002
6. Irani AA, Schechter NM, Craig SS, DeBlois G, Schwartz LB. Two types of human mast cells that have distinct neutral protease compositions. Proc Natl Acad Sci U S A (1986) 83(12):4464-8. doi:10.1073/pnas.83.12.4464
7. Schwartz LB. Analysis of MC(T) and MC(TC) mast cells in tissue. Methods Mol Biol (2006) 315:53-62.
8. Strauss-Albee DM, Horowitz A, Parham P, Blish CA. Coordinated regulation of NK receptor expression in the maturing human immune system. J Immunol (2014) 193(10):4871-9. doi:10.4049/jimmunol.1401821
9. Bradding P. Allergen immunotherapy and mast cells. Clin Exp Allergy (1999) 29(11):1445-8. doi:10.1046/j.1365-2222.1999.00675.x
10. Hofmann AM, Abraham SN. New roles for mast cells in modulating allergic reactions and immunity against pathogens. Curr Opin Immunol (2009) 21(6):679-86. doi:10.1016/j.coi.2009.09.007
11. Galli SJ, Nakae S, Tsai M. Mast cells in the development of adaptive immune responses. Nat Immunol (2005) 6(2):135-42. doi:10.1038/ni1158
12. Rasmussen T, Jensen JF, Ostergaard N, Tanner D, Ziegler T, Norrby PO. On the mechanism of the copper-catalyzed cyclopropanation reaction. Chemistry (2002) 8(1):177-84.
13. Siraganian RP. Mast cell signal transduction from the high-affinity IgE receptor. Curr Opin Immunol (2003) 15(6):639-46. doi:10.1016/j.coi.2003.09.010
14. Sibilano R, Frossi B, Pucillo CE. Mast cell activation: a complex interplay of positive and negative signaling pathways. Eur J Immunol (2014) 44(9):2558-66. doi:10.1002/eji.201444546
15. KalesnikoffJ, Galli SJ. New developments in mast cell biology. Nat Immunol (2008) 9(11):1215-23. doi:10.1038/ni.f.216
16. Iwaki S, Tkaczyk C, Metcalfe DD, Gilfillan AM. Roles of adaptor molecules in mast cell activation. Chem Immunol Allergy (2005) 87:43-58.
17. Hitomi T, Zhang J, Nicoletti LM, Grodzki AC, Jamur MC, Oliver C, et al. Phospholipase D1 regulates high-affinity IgE receptor-induced mast cell degranulation. Blood (2004) 104(13):4122-8. doi:10.1182/blood-2004-06-2091
18. Barbu EA, Zhang J, Berenstein EH, Groves JR, Parks LM, Siraganian RP. The transcription factor Zeb2 regulates signaling in mast cells. J Immunol (2012) 188(12):6278-86. doi:10.4049/jimmunol.1102660
19. Shalit M, Levi-Schaffer F. Challenge of mast cells with increasing amounts of antigen induces desensitization. Clin Exp Allergy (1995) 25(9):896-902. doi:10.1111/j.1365-2222.1995.tb00033.x
20. Norrby K. Mast cells and angiogenesis. APMIS (2002) 110(5):355-71.
21. Bulfone-Paus S, Bahri R. Mast cells as regulators of T cell responses. Front Immunol (2015) 6:394. doi:10.3389/fimmu.2015.00394
22. Goto Y, Kurashima Y, Kiyono H. The gut microbiota and inflammatory bowel disease. Curr Opin Rheumatol (2015) 27(4):388-96.
23. Marshall JS. Mast-cell responses to pathogens. Nat Rev Immunol (2004) 4(10):787-99. doi:10.1038/nri1460
24. Metz M, Siebenhaar F, Maurer M. Mast cell functions in the innate skin immune system. Immunobiology (2008) 213(3-4):251-60. doi:10.1016/j.imbio.2007.10.017
25. Varadaradjalou S, Féger F, Thieblemont N, Hamouda NB, Pleau JM, Dy M, et al. Toll-like receptor 2 (TLR2) and TLR4 differentially activate human mast cells. Eur J Immunol (2003) 33(4):899-906. doi:10.1002/eji.200323830
26. McCurdy JD, Olynych TJ, Maher LH, Marshall JS. Cutting edge: distinct toll-like receptor 2 activators selectively induce different classes of mediator production from human mast cells. J Immunol (2003) 170(4):1625-9. doi:10.4049/jimmunol.170.4.1625
27. Orinska Z, Bulanova E, Budagian V, Metz M, Maurer M, Bulfone-Paus S. TLR3-induced activation of mast cells modulates CD8+ T-cell recruitment. Blood (2005) 106(3):978-87. doi:10.1182/blood-2004-07-2656
28. Kulka M, Alexopoulou L, Flavell RA, Metcalfe DD. Activation of mast cells by double-stranded RNA: evidence for activation through toll-like receptor 3. J Allergy Clin Immunol (2004) 114(1):174-82. doi:10.1016/j.jaci.2004.03.049
29. Stelekati E, Bahri R, D'Orlando O, Orinska Z, Mittrücker HW, Langenhaun R, et al. Mast cell-mediated antigen presentation regulates CD8+ T cell effector functions. Immunity (2009) 31(4):665-76. doi:10.1016/j.immuni.2009.08.022
30. Nakae S, Suto H, Iikura M, Kakurai M, Sedgwick JD, Tsai M, et al. Mast cells enhance T cell activation: importance of mast cell costimulatory molecules and secreted TNF. J Immunol (2006) 176(4):2238-48. doi:10.4049/jimmunol.176.4.2238
31. Xiang Z, Block M, Löfman C, Nilsson G. IgE-mediated mast cell degranulation and recovery monitored by time-lapse photography. J Allergy Clin Immunol (2001) 108(1):116-21. doi:10.1067/mai.2001.116124
32. Basu S, Fenton MJ. Toll-like receptors: function and roles in lung disease. Am J Physiol Lung Cell Mol Physiol (2004) 286(5):L887-92. doi:10.1152/ajplung.00323.2003
33. Supajatura V, Ushio H, Nakao A, Akira S, Okumura K, Ra C, et al. Differential responses of mast cell toll-like receptors 2 and 4 in allergy and innate immunity. J Clin Invest (2002) 109(10):1351-9. doi:10.1172/JCI0214704
34. Garcia-Faroldi G, Melo FR, Rönnberg E, Grujic M, Pejler G. Active caspase-3 is stored within secretory compartments of viable mast cells. J Immunol (2013) 191(3):1445-52. doi:10.4049/jimmunol.1300216
35. Rauter I, Krauth MT, Westritschnig K, Horak F, Flicker S, Gieras A, et al. Mast cell-derived proteases control allergic inflammation through cleavage of IgE. J Allergy Clin Immunol (2008) 121(1):197-202. doi:10.1016/j.jaci.2007.08.015
36. Gordon JR, Galli SJ. Mast cells as a source of both preformed and immunologically inducible TNF-alpha/cachectin. Nature (1990) 346(6281):274-6. doi:10.1038/346274a0
37. De Filippo K, Dudeck A, Hasenberg M, Nye E, van Rooijen N, Hartmann K, et al. Mast cell and macrophage chemokines CXCL1/CXCL2 control the early stage of neutrophil recruitment during tissue inflammation. Blood (2013) 121(24):4930-7. doi:10.1182/blood-2013-02-486217
38. Berenbaum F, Humbert L, Bereziat G, Thirion S. Concomitant recruitment of ERK1/2 and p38 MAPK signalling pathway is required for activation of cytoplasmic phospholipase A2 via ATP in articular chondrocytes. J Biol Chem (2003) 278(16):13680-7. doi:10.1074/jbc. M211570200
39. Malaviya R, Abraham SN. Role of mast cell leukotrienes in neutrophil recruitment and bacterial clearance in infectious peritonitis. J Leukoc Biol (2000) 67(6):841-6.
40. Boyce JA. Mast cells and eicosanoid mediators: a system of reciprocal paracrine and autocrine regulation. Immunol Rev (2007) 217:168-85. doi:10.1111/j.1600-065X.2007.00512.x
41. Steiner DR, Gonzalez NC, Wood JG. Mast cells mediate the microvascular inflammatory response to systemic hypoxia. J Appl Physiol (1985) (2003) 94(1):325-34. doi:10.1152/japplphysiol.00637.2002
42. Wood JG, Johnson JS, Mattioli LF, Gonzalez NC. Systemic hypoxia increases leukocyte emigration and vascular permeability in conscious rats. J Appl Physiol (1985) (2000) 89(4):1561-8.
43. Guzy RD, Schumacker PT. Oxygen sensing by mitochondria at complex III: the paradox of increased reactive oxygen species during hypoxia. Exp Physiol (2006) 91(5):807-19. doi:10.1113/expphysiol.2006.033506
44. Dix R, Orth T, Allen J, Wood JG, Gonzalez NC. Activation of mast cells by systemic hypoxia, but not by local hypoxia, mediates increased leukocyte-endothelial adherence in cremaster venules. J Appl Physiol (1985) (2003) 95(6):2495-502.
45. Chao J, Blanco G, Wood JG, Gonzalez NC. Renin released from mast cells activated by circulating MCP-1 initiates the microvascular phase of the systemic inflammation of alveolar hypoxia. Am J Physiol Heart Circ Physiol (2011) 301(6):H2264-70.
46. Yang MQ, Ma YY, Tao SF, Ding J, Rao LH, Jiang H, et al. Mast cell degranulation promotes ischemia-reperfusion injury in rat liver. J Surg Res (2014) 186(1):170-8. doi:10.1016/j.jss.2013.08.021
47. Yang MQ, Ma YY, Ding J, Li JY. The role of mast cells in ischemia and reperfusion injury. Inflamm Res (2014) 63(11):899-905. doi:10.1007/s00011-014-0763-z
48. Kimura T, Andoh A, Fujiyama Y, Saotome T, Bamba T. A blockade of complement activation prevents rapid intestinal ischaemia-reperfusion injury by modulating mucosal mast cell degranulation in rats. Clin Exp Immunol (1998) 111(3):484-90. doi:10.1046/j.1365-2249.1998.00518.x
49. Becker BF, Kupatt C, Massoudy P, Zahler S. Reactive oxygen species and nitric oxide in myocardial ischemia and reperfusion. Z Kardiol (2000) 89(Suppl 9):IX/88-91. doi:10.1007/s003920070037
50. Kuehn HS, Gilfillan AM. G protein-coupled receptors and the modification of FcepsilonRI-mediated mast cell activation. Immunol Lett (2007) 113(2):59-69. doi:10.1016/j.imlet.2007.08.007
51. Nguyen M, Solle M, Audoly LP, Tilley SL, Stock JL, McNeish JD, et al. Receptors and signaling mechanisms required for prostaglandin E2-mediated regulation of mast cell degranulation and IL-6 production. J Immunol (2002) 169(8):4586-93. doi:10.4049/jimmunol.169.8.4586
52. Silver RB, Reid AC, Mackins CJ, Askwith T, Schaefer U, Herzlinger D, et al. Mast cells: a unique source of renin. Proc Natl Acad Sci U S A (2004) 101(37):13607-12. doi:10.1073/pnas.0403208101
53. Mackins CJ, Kano S, Seyedi N, Schäfer U, Reid AC, Machida T, et al. Cardiac mast cell-derived renin promotes local angiotensin formation, norepinephrine release, and arrhythmias in ischemia/reperfusion. J Clin Invest (2006) 116(4):1063-70. doi:10.1172/JCI25713
54. Koda K, Salazar-Rodriguez M, Corti F, Chan NY, Estephan R, Silver RB, et al. Aldehyde dehydrogenase activation prevents reperfusion arrhythmias by inhibiting local renin release from cardiac mast cells. Circulation (2010) 122(8):771-81. doi:10.1161/CIRCULATIONAHA.110.952481
55. Hartman J, Frishman WH. Inflammation and atherosclerosis: a review of the role of interleukin-6 in the development of atherosclerosis and the potential for targeted drug therapy. Cardiol Rev (2014) 22(3):147-51. doi:10.1097/CRD.0000000000000021
56. Hansson GK, Jonasson L, Seifert PS, Stemme S. Immune mechanisms in atherosclerosis. Arteriosclerosis (1989) 9(5):567-78. doi:10.1161/01.ATV.9.5.567
57. Medzhitov R, Janeway C Jr. Innate immunity. N Engl J Med (2000) 343(5):338-44. doi:10.1056/NEJM200008033430506
58. Hansson GK, Libby P, Schönbeck U, Yan ZQ. Innate and adaptive immunity in the pathogenesis of atherosclerosis. Circ Res (2002) 91(4):281-91. doi:10.1161/01.RES.0000029784.15893.10
59. Kranzhöfer R, Schmidt J, Pfeiffer CA, Hagl S, Libby P, Kübler W. Angiotensin induces inflammatory activation of human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol (1999) 19(7):1623-9. doi:10.1161/01.ATV.19.7.1623
60. Haley KJ, Lilly CM, Yang JH, Feng Y, Kennedy SP, Turi TG, et al. Overexpression of eotaxin and the CCR3 receptor in human atherosclerosis: using genomic technology to identify a potential novel pathway of vascular inflammation. Circulation (2000) 102(18):2185-9. doi:10.1161/01.CIR.102.18.2185
61. Kovanen PT. Role of mast cells in atherosclerosis. Chem Immunol (1995) 62:132-70. doi:10.1159/000424598
62. Bot I, de Jager SC, Zernecke A, Lindstedt KA, van Berkel TJ, Weber C, et al. Perivascular mast cells promote atherogenesis and induce plaque destabilization in apolipoprotein E-deficient mice. Circulation (2007) 115(19):2516-25. doi:10.1161/CIRCULATIONAHA.106.660472
63. Laine P, Kaartinen M, Penttilä A, Panula P, Paavonen T, Kovanen PT. Association between myocardial infarction and the mast cells in the adventitia of the infarct-related coronary artery. Circulation (1999) 99(3):361-9. doi:10.1161/01.CIR.99.3.361
64. Chávez-Sánchez L, Espinosa-Luna JE, Chávez-Rueda K, Legorreta-Haquet MV, Montoya-Díaz E, Blanco-Favela F. Innate immune system cells in atherosclerosis. Arch Med Res (2014) 45(1):1-14. doi:10.1016/j.arcmed.2013.11.007
65. Wang J, Cheng X, Xiang MX, Alanne-Kinnunen M, Wang JA, Chen H, et al. IgE stimulates human and mouse arterial cell apoptosis and cytokine expression and promotes atherogenesis in Apoe-/-mice. J Clin Invest (2011) 121(9):3564-77. doi:10.1172/JCI46028
66. den Dekker WK, Tempel D, Bot I, Biessen EA, Joosten LA, Netea MG, et al. Mast cells induce vascular smooth muscle cell apoptosis via a toll-like receptor 4 activation pathway. Arterioscler Thromb Vasc Biol (2012) 32(8):1960-9. doi:10.1161/ATVBAHA.112.250605
67. Zhi X, Xu C, Zhang H, Tian D, Li X, Ning Y, et al. Tryptase promotes atherosclerotic plaque haemorrhage in ApoE-/-mice. PLoS One (2013) 8(4):e60960. doi:10.1371/journal.pone.0060960
68. Yeong P, Ning Y, Xu Y, Li X, Yin L. Tryptase promotes human monocyte-derived macrophage foam cell formation by suppressing LXRalpha activation. Biochim Biophys Acta (2010) 1801(5):567-76. doi:10.1016/j.bbalip.2010.01.011
69. Galli SJ, Gordon JR, Wershil BK. Cytokine production by mast cells and basophils. Curr Opin Immunol (1991) 3(6):865-72. doi:10.1016/S0952-7915(05)80005-6
70. Swedenborg J, Mayranpaa MI, Kovanen PT. Mast cells: important players in the orchestrated pathogenesis of abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol (2011) 31(4):734-40. doi:10.1161/ATVBAHA.110.213157
71. Sun J, Sukhova GK, Yang M, Wolters PJ, MacFarlane LA, Libby P, et al. Mast cells modulate the pathogenesis of elastase-induced abdominal aortic aneurysms in mice. J Clin Invest (2007) 117(11):3359-68. doi:10.1172/JCI31311
72. Tsuruda T, Kato J, Hatakeyama K, Kojima K, Yano M, Yano Y, et al. Adventitial mast cells contribute to pathogenesis in the progression of abdominal aortic aneurysm. Circ Res (2008) 102(11):1368-77. doi:10.1161/CIRCRESAHA.108.173682
73. Hackam DG, Thiruchelvam D, Redelmeier DA. Angiotensin-converting enzyme inhibitors and aortic rupture: a population-based case-control study. Lancet (2006) 368(9536):659-65. doi:10.1016/S0140-6736(06)69250-7
74. Liao S, Miralles M, Kelley BJ, Curci JA, Borhani M, Thompson RW. Suppression of experimental abdominal aortic aneurysms in the rat by treatment with angiotensin-converting enzyme inhibitors. J Vasc Surg (2001) 33(5):1057-64. doi:10.1067/mva.2001.112810
75. Chamberlain CM, Ang LS, Boivin WA, Cooper DM, Williams SJ, Zhao H, et al. Perforin-independent extracellular granzyme B activity contributes to abdominal aortic aneurysm. Am J Pathol (2010) 176(2):1038-49. doi:10.2353/ajpath.2010.090700
76. Bot I, Shi GP, Kovanen PT. Mast cells as effectors in atherosclerosis. Arterioscler Thromb Vasc Biol (2015) 35(2):265-71. doi:10.1161/ATVBAHA.114.303570
77. Kamat BR, Galli SJ, Barger AC, Lainey LL, Silverman KJ. Neovascularization and coronary atherosclerotic plaque: cinematographic localization and quantitative histologic analysis. Hum Pathol (1987) 18(10):1036-42. doi:10.1016/S0046-8177(87)80220-4
78. Kaartinen M, Penttila A, Kovanen PT. Mast cells accompany microvessels in human coronary atheromas: implications for intimal neovascularization and hemorrhage. Atherosclerosis (1996) 123(1-2):123-31. doi:10.1016/0021-9150(95)05794-3
79. Sun J, Sukhova GK, Wolters PJ, Yang M, Kitamoto S, Libby P, et al. Mast cells promote atherosclerosis by releasing proinflammatory cytokines. Nat Med (2007) 13(6):719-24. doi:10.1038/nm1601
80. Leskinen MJ, Lindstedt KA, Wang Y, Kovanen PT. Mast cell chymase induces smooth muscle cell apoptosis by a mechanism involving fibronectin degradation and disruption of focal adhesions. Arterioscler Thromb Vasc Biol (2003) 23(2):238-43. doi:10.1161/01.ATV.0000051405.68811.4D
81. Leskinen MJ, Heikkilä HM, Speer MY, Hakala JK, Laine M, Kovanen PT, et al. Mast cell chymase induces smooth muscle cell apoptosis by disrupting NF-kappaB-mediated survival signaling. Exp Cell Res (2006) 312(8):1289-98. doi:10.1016/j.yexcr.2005.12.033
82. Heikkilä HM, Lätti S, Leskinen MJ, Hakala JK, Kovanen PT, Lindstedt KA. Activated mast cells induce endothelial cell apoptosis by a combined action of chymase and tumor necrosis factor-alpha. Arterioscler Thromb Vasc Biol (2008) 28(2):309-14. doi:10.1161/ATVBAHA.107.151340
83. Kokkonen JO, Kovanen PT. Low-density-lipoprotein binding by mast-cell granules. Demonstration of binding of apolipoprotein B to heparin proteoglycan of exocytosed granules. Biochem J (1987) 241(2):583-9. doi:10.1042/bj2410583
84. Kokkonen JO. Stimulation of rat peritoneal mast cells enhances uptake of low density lipoproteins by rat peritoneal macrophages in vivo. Atherosclerosis (1989) 79(2-3):213-23. doi:10.1016/0021-9150(89)90126-3
85. Korkmaz ME, Oto A, Saraçlar Y, Oram E, Oram A, Ugurlu S, et al. Levels of IgE in the serum of patients with coronary arterial disease. Int J Cardiol (1991) 31(2):199-204. doi:10.1016/0167-5273(91)90216-C
86. Willems S, van der Velden D, Quax PH, de Borst GJ, de Vries JP, Moll FL, et al. Circulating immunoglobulins are not associated with intraplaque mast cell number and other vulnerable plaque characteristics in patients with carotid artery stenosis. PLoS One (2014) 9(2):e88984. doi:10.1371/journal.pone.0088984
87. de Vries MR, Wezel A, Schepers A, van Santbrink PJ, WoodruffTM, Niessen HW, et al. Complement factor C5a as mast cell activator mediates vascular remodelling in vein graft disease. Cardiovasc Res (2013) 97(2):311-20. doi:10.1093/cvr/cvs312
88. Kelley J, Hemontolor G, Younis W, Li C, Krishnaswamy G, Chi DS. Mast cell activation by lipoproteins. Methods Mol Biol (2006) 315:341-8.
89. Sick E, Brehin S, André P, Coupin G, Landry Y, Takeda K, et al. Advanced glycation end products (AGEs) activate mast cells. Br J Pharmacol (2010) 161(2):442-55. doi:10.1111/j.1476-5381.2010.00905.x
90. Li WW, Guo TZ, Liang DY, Sun Y, Kingery WS, Clark JD. Substance P signaling controls mast cell activation, degranulation, and nociceptive sensitization in a rat fracture model of complex regional pain syndrome. Anesthesiology (2012) 116(4):882-95. doi:10.1097/ALN.0b013e31824bb303
91. Murray DB, Gardner JD, Brower GL, Janicki JS. Endothelin-1 mediates cardiac mast cell degranulation, matrix metalloproteinase activation, and myocardial remodeling in rats. Am J Physiol Heart Circ Physiol (2004) 287(5):H2295-9. doi:10.1152/ajpheart.00048.2004
92. Vliagoftis H. Thrombin induces mast cell adhesion to fibronectin: evidence for involvement of protease-activated receptor-1. J Immunol (2002) 169(8):4551-8. doi:10.4049/jimmunol.169.8.4551
93. Galli SJ. New concepts about the mast cell. N Engl J Med (1993) 328(4):257-65. doi:10.1056/NEJM199301283280408
94. Schwartz LB, Irani AM, Roller K, Castells MC, Schechter NM. Quantitation of histamine, tryptase, and chymase in dispersed human T and TC mast cells. J Immunol (1987) 138(8):2611-5.
95. Reynolds DS, Gurley DS, Stevens RL, Sugarbaker DJ, Austen KF, Serafin WE. Cloning of cDNAs that encode human mast cell carboxypeptidase A, and comparison of the protein with mouse mast cell carboxypeptidase A and rat pancreatic carboxypeptidases. Proc Natl Acad Sci U S A (1989) 86(23):9480-4. doi:10.1073/pnas.86.23.9480
96. Vanderslice P, Ballinger SM, Tam EK, Goldstein SM, Craik CS, Caughey GH. Human mast cell tryptase: multiple cDNAs and genes reveal a multigene serine protease family. Proc Natl Acad Sci U S A (1990) 87(10):3811-5. doi:10.1073/pnas.87.10.3811
97. Urata H, Kinoshita A, Misono KS, Bumpus FM, Husain A. Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the human heart. J Biol Chem (1990) 265(36):22348-57.
98. DeSchryver-Kecskemeti K, Williamson JR, Jakschik BA, Clouse RE, Alpers DH. Mast cell granules within endothelial cells: a possible signal in the inflammatory process? Mod Pathol (1992) 5(3):343-7.
99. Triggiani M, Hubbard WC, Chilton FH. Synthesis of 1-acyl-2-acetyl-sn-glycero-3-phosphocholine by an enriched preparation of the human lung mast cell. J Immunol (1990) 144(12):4773-80.
100. Krüger-Krasagakes S, Möller A, Kolde G, Lippert U, Weber M, Henz BM. Production of interleukin-6 by human mast cells and basophilic cells. J Invest Dermatol (1996) 106(1):75-9. doi:10.1111/1523-1747.ep12327815
101. Klein LM, Lavker RM, Matis WL, Murphy GF. Degranulation of human mast cells induces an endothelial antigen central to leukocyte adhesion. Proc Natl Acad Sci U S A (1989) 86(22):8972-6. doi:10.1073/pnas.86.22.8972
102. Blirando K, Hneino M, Martelly I, Benderitter M, Milliat F, François A. Mast cells and ionizing radiation induce a synergistic expression of inflammatory genes in endothelial cells by a mechanism involving p38alpha MAP kinase and (p65) NF-kappaB activation. Radiat Res (2012) 178(6):556-67. doi:10.1667/RR3058.1
103. Kalsner S, Richards R. Coronary arteries of cardiac patients are hyperreactive and contain stores of amines: a mechanism for coronary spasm. Science (1984) 223(4643):1435-7. doi:10.1126/science.6701530
104. Forman MB, Oates JA, Robertson D, Robertson RM, Roberts LJ II, Virmani R. Increased adventitial mast cells in a patient with coronary spasm. N Engl J Med (1985) 313(18):1138-41. doi:10.1056/NEJM198510313131807
105. Fernex M. The Mast-Cell System: Its Relationship to Atherosclerosis, Fibrosis and Eosinophils. Baltimore, MD: Williams & Wilkins (1968).
106. Jeziorska M, McCollum C, Woolley DE. Mast cell distribution, activation, and phenotype in atherosclerotic lesions of human carotid arteries. J Pathol (1997) 182(1):115-22. doi:10.1002/(SICI)1096-9896(199705)182:1<115::AID-PATH806>3.0.CO;2-9
107. Dileepan KN, Stechschulte DJ. Endothelial cell activation by mast cell mediators. Methods Mol Biol (2006) 315:275-94.
108. Fernex M, Sternby NH. Mast cells and coronary heart disease. Relationship between number of mast cells in the myocardium, severity of coronary atherosclerosis and myocardial infarction in an autopsy series of 672 cases. Acta Pathol Microbiol Scand (1964) 62:525-38.
109. Marks RM, Roche WR, Czerniecki M, Penny R, Nelson DS. Mast cell granules cause proliferation of human microvascular endothelial cells. Lab Invest (1986) 55(3):289-94.
110. Atkinson JB, Harlan CW, Harlan GC, Virmani R. The association of mast cells and atherosclerosis: a morphologic study of early atherosclerotic lesions in young people. Hum Pathol (1994) 25(2):154-9. doi:10.1016/0046-8177(94)90271-2
111. Kokkonen JO, Vartiainen M, Kovanen PT. Low density lipoprotein degradation by secretory granules of rat mast cells. Sequential degradation of apolipoprotein B by granule chymase and carboxypeptidase A. J Biol Chem (1986) 261(34):16067-72.
112. Lindstedt KA. Inhibition of macrophage-mediated low density lipoprotein oxidation by stimulated rat serosal mast cells. J Biol Chem (1993) 268(11):7741-6.
113. Smith DD, Tan X, Raveendran VV, Tawfik O, Stechschulte DJ, Dileepan KN. Mast cell deficiency attenuates progression of atherosclerosis and hepatic steatosis in apolipoprotein E-null mice. Am J Physiol Heart Circ Physiol (2012) 302(12):H2612-21. doi:10.1152/ajpheart.00879.2011
114. Heikkilä HM, Trosien J, Metso J, Jauhiainen M, Pentikäinen MO, Kovanen PT, et al. Mast cells promote atherosclerosis by inducing both an atherogenic lipid profile and vascular inflammation. J Cell Biochem (2010) 109(3):615-23. doi:10.1002/jcb.22443
115. Barnes PJ. Histamine receptors in the lung. Agents Actions Suppl (1991) 33:103-22.
116. Hill SJ. Multiple histamine receptors: properties and functional characteristics. Biochem Soc Trans (1992) 20(1):122-5. doi:10.1042/bst0200122
117. Elenkov IJ, Webster E, Papanicolaou DA, Fleisher TA, Chrousos GP, Wilder RL. Histamine potently suppresses human IL-12 and stimulates IL-10 production via H2 receptors. J Immunol (1998) 161(5):2586-93.
118. Dileepan KN, Lorsbach RB, Stechschulte DJ. Mast cell granules inhibit macrophage-mediated lysis of mastocytoma cells (P815) and nitric oxide production. J Leukoc Biol (1993) 53(4):446-53.
119. Beer DJ, MatloffSM, Rocklin RE. The influence of histamine on immune and inflammatory responses. Adv Immunol (1984) 35:209-68. doi:10.1016/S0065-2776(08)60577-5
120. Jeannin P, Delneste Y, Gosset P, Molet S, Lassalle P, Hamid Q, et al. Histamine induces interleukin-8 secretion by endothelial cells. Blood (1994) 84(7):2229-33.
121. Li Y, Chi L, Stechschulte DJ, Dileepan KN. Histamine-induced production of interleukin-6 and interleukin-8 by human coronary artery endothelial cells is enhanced by endotoxin and tumor necrosis factor-alpha. Microvasc Res (2001) 61(3):253-62. doi:10.1006/mvre.2001.2304
122. Hough LB. Genomics meets histamine receptors: new subtypes, new receptors. Mol Pharmacol (2001) 59(3):415-9.
123. Benovic JL, DeBlasi A, Stone WC, Caron MG, Lefkowitz RJ. Beta-adrenergic receptor kinase: primary structure delineates a multigene family. Science (1989) 246(4927):235-40. doi:10.1126/science.2552582
124. Willets JM, Taylor AH, Shaw H, Konje JC, Challiss RA. Selective regulation of H1 histamine receptor signaling by G protein-coupled receptor kinase 2 in uterine smooth muscle cells. Mol Endocrinol (2008) 22(8):1893-907. doi:10.1210/me.2007-0463
125. Iwata K, Luo J, Penn RB, Benovic JL. Bimodal regulation of the human H1 histamine receptor by G protein-coupled receptor kinase 2. J Biol Chem (2005) 280(3):2197-204. doi:10.1074/jbc. M408834200
126. Walsh GM, Annunziato L, Frossard N, Knol K, Levander S, Nicolas JM, et al. New insights into the second generation antihistamines. Drugs (2001) 61(2):207-36. doi:10.2165/00003495-200161020-00006
127. Sakata Y, Komamura K, Hirayama A, Nanto S, Kitakaze M, Hori M, et al. Elevation of the plasma histamine concentration in the coronary circulation in patients with variant angina. Am J Cardiol (1996) 77(12):1121-6. doi:10.1016/S0002-9149(96)00147-6
128. Tan X, Essengue S, Talreja J, Reese J, Stechschulte DJ, Dileepan KN. Histamine directly and synergistically with lipopolysaccharide stimulates cyclooxygenase-2 expression and prostaglandin I(2) and E(2) production in human coronary artery endothelial cells. J Immunol (2007) 179(11):7899-906. doi:10.4049/jimmunol.179.11.7899
129. Bottaro D, Shepro D, Peterson S, Hechtman HB. Serotonin, histamine, and norepinephrine mediation of endothelial and vascular smooth muscle cell movement. Am J Physiol (1985) 248(3 Pt 1):C252-7.
130. Bell L, Madri JA. Effect of platelet factors on migration of cultured bovine aortic endothelial and smooth muscle cells. Circ Res (1989) 65(4):1057-65. doi:10.1161/01.RES.65.4.1057
131. Miyazawa N, Watanabe S, Matsuda A, Kondo K, Hashimoto H, Umemura K, et al. Role of histamine H1 and H2 receptor antagonists in the prevention of intimal thickening. Eur J Pharmacol (1998) 362(1):53-9. doi:10.1016/S0014-2999(98)00716-X
132. Takagishi T, Sasaguri Y, Nakano R, Arima N, Tanimoto A, Fukui H, et al. Expression of the histamine H1 receptor gene in relation to atherosclerosis. Am J Pathol (1995) 146(4):981-8.
133. Talreja J, Kabir MH, B Filla M, Stechschulte DJ, Dileepan KN. Histamine induces toll-like receptor 2 and 4 expression in endothelial cells and enhances sensitivity to Gram-positive and Gram-negative bacterial cell wall components. Immunology (2004) 113(2):224-33. doi:10.1111/j.1365-2567.2004.01946.x
134. Raveendran VV, Tan X, Sweeney ME, Levant B, Slusser J, Stechschulte DJ, et al. Lipopolysaccharide induces H1 receptor expression and enhances histamine responsiveness in human coronary artery endothelial cells. Immunology (2011) 132(4):578-88. doi:10.1111/j.1365-2567.2010.03403.x
135. Raveendran VV, Smith DD, Tan X, Sweeney ME, Reed GA, Flynn CA, et al. Chronic ingestion of H1-antihistamines increase progression of atherosclerosis in apolipoprotein E-/-mice. PLoS One (2014) 9(7):e102165. doi:10.1371/journal.pone.0102165
136. Harman D. Pig atherosclerosis. Effect of the antihistamine, chlorpheniramine, on atherogenesis and serum lipids. J Atheroscler Res (1969) 10(1):77-84. doi:10.1016/S0368-1319(69)80084-0
137. Rozenberg I, Sluka SH, Rohrer L, Hofmann J, Becher B, Akhmedov A, et al. Histamine H1 receptor promotes atherosclerotic lesion formation by increasing vascular permeability for low-density lipoproteins. Arterioscler Thromb Vasc Biol (2010) 30(5):923-30. doi:10.1161/ATVBAHA.109.201079